Introduction: Human papillomavirus (HPV) is one of the world's most common sexually
transmitted infections, and has been associated with a number of cervical and non-cervical …

Background: Despite screening, cervical cancer (CC) remains a serious health care
problem. Because human papillomavirus (HPV) is the necessary cause of CC, the …

Introduction The World Health Organization (WHO) recommends that human papillomavirus
(HPV) vaccination programs are established to be cost-effective before implementation …

The recent approval of human papillomavirus (HPV) vaccine means that decision makers
need information beyond that available from randomized clinical trials to recommend …

Fifteen years following the approval of the first human papillomavirus (HPV) vaccine,
cervical cancer continues to be a significant source of morbidity and mortality among women …

Introduction: Many economic evaluations of HPV vaccination have been published, but most
have focused on the prevention of cervical disease as a primary health outcome. The cost …

A critical review of cost-effectiveness analyses of HPV vaccination in males was conducted
and nine studies were identified in different countries. Due to the heterogeneity among these …

Objective This study aimed at evaluating the cost-effectiveness of human papillomavirus
virus (HPV) vaccination in France, using a generally applicable succinct cohort model …

Background: With promising efficacy results from randomized control trials of human
papillomavirus (HPV) vaccines and the availability of new screening paradigms …

Background The success of human papillomavirus (HPV) national immunization program
depends on effective strategies in optimizing the uptake of HPV vaccine. Given the …